Three sessions instead of a course: feasibility of brief pain reprocessing therapy in fibromyalgia

Fibromyalgia is the index condition for nociplastic pain, yet most of what we offer patients was designed for other mechanisms. The interesting claim in this pilot is not the effect size but the compression: a protocol usually delivered over eight to twelve weeks was cut to three sessions and moved onto video, and the authors then asked whether anything survived. For a clinician with a waiting list, that question matters more than another confirmation that longer programmes work.

How it was run, and what the protocol contains

The design is a single-arm, open-label pilot at the University of Michigan (NCT06208514). Of 154 people screened, 41 completed baseline questionnaires and 35 started treatment. The sample was 30 of 35 women, mean age 44.2 years (SD 13.8, range 19-70), with baseline pain of 5.83 (SD 2.12) and a PROMIS interference T-score of 64.0 – roughly 1.4 standard deviations above the general population mean. Participants attended three weekly one-to-one sessions on Zoom, nominally 60 minutes but booked into 90-minute slots to absorb late arrivals and connection failures. Up to two reschedules were allowed inside a five-slot window; miss that and the participant was out.

The content is a compressed version of pain reprocessing therapy, and its elements are worth naming because that is the deliverable here; the detailed session outline sits in the paper's supplementary material rather than the main text, so what follows is the set of components, not a delivery sequence. Pain neuroscience education that reframes fibromyalgia pain as a learned, reversible central nervous system signal rather than a readout of tissue damage. Mindfulness meditation and somatic tracking – attending to the painful sensation deliberately, with a stance of curiosity and safety rather than alarm. Positive-affect work: guided imagery, plus identifying and actually scheduling personally enjoyable activity. Imaginal and in-vivo graded exposure to the movements and sensations the patient has been avoiding. Goal setting so the exposure plan continues without a therapist. Pre-recorded meditation and imagery files carried the between-session practice.

The outcome pattern has one feature worth noticing: benefit kept accruing after the sessions stopped. Effect sizes were moderate at 1 month and large at 2 and 3 months across all three outcomes, and the proportion rating themselves much or very much improved rose from 20.7% to 25.9% to 42.3%. That is consistent with a protocol whose active ingredient is a skill the patient keeps rehearsing – though it is equally consistent with attrition, since the assessed sample shrank from 33 to 29 to 27 to 26 and the least-improved are the likeliest to stop answering.

What to do with this on Monday

The trial cannot tell you whom to select: the authors state that moderators and predictors of response were not examined. What it does hand you is the frame they recruited into – a confirmed nociplastic picture with no active tissue pathology – and the exclusions they applied: co-occurring structural or inflammatory causes, concurrent pain psychotherapy, active litigation. Three sessions is a realistic trial of the model rather than a course of treatment; if a patient shows nothing by 1 month, you have spent very little.

Three cautions and one disclosure before you promise anything. Every session was delivered by the pain psychologist who wrote the manual, so the ceiling you are seeing is expert-delivered; the authors flag this themselves. Roughly half the sample did not reach a 30% reduction at any timepoint, and the design can identify neither which component did the work nor who responds. On safety, three adverse events were recorded, all judged unrelated to the intervention. One author reports consulting for Lin Health and for the Pain Reprocessing Therapy Center.

One more thing to read before citing this. The registration (NCT06208514) lists change in pain rating as the primary outcome, whereas the publication presents feasibility and acceptability as primary and efficacy as secondary. The registry entry stands under a different programme name, specifies the 17-item version of the Tampa Scale of Kinesiophobia rather than the 13-item version reported here, targets 125 participants and is still recruiting. What you are reading is an interim report on the fibromyalgia subset, not a completed trial.